Effect of Urinary Kallidinogenase on Transforming Growth Factor-β₁ and High-Sensitivity C-Reactive Protein Expression in Rat Focal Cerebral Ischemic Injury

BE 1 Ting-Fang Dong
BD 2 Hai-Xia Lv
DF 3 Xiao-Lu Niu
CEG 3 Yong-Kun Gui
AEG 3 Ping Zhang
BF 3 Hai-Qing Yan
DF 3 Tong Li

Corresponding Author: Ping Zhang, e-mail: pingzhangdoc@126.com
Source of support: Departmental sources

Background: In this study we investigated the effect of urinary kallidinogenase (UK) on transforming growth factor beta 1 (TGF-β₁) expression in brain tissue. We also explored the neuroprotective mechanism of UK against ischemic injury by measuring serum high-sensitivity C-reactive protein (hs-CRP) level changes after rat cerebral ischemic injury.

Material/Methods: The rat middle cerebral artery ischemia/reperfusion model was established using the suture method. Sprague-Dawley rats were randomly divided into 3 groups: treatment, Gegen control, and blank control. Each group was subsequently divided into 5 subgroups according to time (6, 12, 24, 48, and 72 h). Rats in the treatment group were administered UK as treatment. TGF-β₁ expression was observed at each time point using SABC and immunohistochemical staining methods to estimate cerebral infarct volume percentage. Serum hs-CRP levels were also measured.

Results: TGF-β₁ protein expression in ischemic brain tissues of the treatment group significantly increased at each time point (P<0.01) compared with both control groups. Treatment group serum hs-CRP levels significantly decreased at each time point (P<0.05) compared with both control groups.

Conclusions: UK exerts a neuroprotective effect by upregulating TGF-β₁ expression and inhibiting excessive inflammatory responses.

MeSH Keywords: Activating Transcription Factor 1 • Hypoxia-Ischemia, Brain • Neurology

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/892724

MeSH: 2307 3 3 30
Background

The main chemical component of human urinary kallidinogenase (UK) is tissue kininogenase 1 (HK1). In plasma, HK1 catalyzes kininogen hydrolysis into kallidin, which can combine with G protein-coupled receptors (B1 and B2 receptors) in endothelial cells. Only the B2 receptor of kinin is found in normal tissues; B1 receptors are expressed only when damage is induced. In response to ischemic and cellular injuries, such as cerebral infarction, vascular endothelial cells at ischemic sites express B1 receptors. Kallidin then binds to the B1 receptor to promote nitric oxide release, thereby selectively dilating micro-arteries in ischemic tissues [1]. UK is widely used in clinical treatment.

Transforming growth factor beta 1 (TGF-β1), a cytokine that can attenuate inflammation, is considered an effective immunomodulator. The relationship between TGF-β1 and cerebral ischemia has recently gained research attention because the expression and generation of TGF-β1 may provide insights into the protection and repair of ischemic/hypoxic brain tissues [2]. High-sensitivity C-reactive protein (hs-CRP) is a serum biochemical marker that reflects systemic inflammation and is involved in the occurrence and development of ischemic stroke. The ischemia was closely associated with inflammation. UK can promote angiogenesis and reduce inflammatory cell infiltration, which can protect neurons during ischemia. Increased TGF-β1 expression may be a protective response to ischemic brain damage. C-reactive protein (CRP), a systemic inflammation indicator, may predict ischemic burden. It is important to illuminate the relationship between UK, TGF-β1, and hs-CRP for ischemic therapy.

In this study, a focal cerebral ischemia model of rat middle cerebral artery occlusion via suture was established to observe the effect of UK on TGF-β1 expression and serum hs-CRP level changes in rat brain and to explore the neuroprotective mechanism of UK against focal cerebral ischemia.

Material and Methods

Model preparation

The Henan Provincial Experimental Animal Centre (license number: SCXK (Yu) 2010-0002) provided 108 healthy male Sprague-Dawley rats (weight: 220–260 g). This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The animal use protocol was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Xinxiang Medical University. The rats were randomly divided into 3 groups: blank control group (BC, n=36), treatment group (TG, n=36), and Gegen control group (GC, n=36). Rats in each group were further divided into 3 subgroups according to time: 6, 12, 24, 48, and 72 h. For each group, 12 rats were assigned to the 72-h time point, of which 6 were designated for tissue section and 6 were designated for triphenyltetrazolium chloride (TTC) staining to estimate infarct volume percentage. The remaining rats from each group were evenly divided among the remaining time points for tissue section analysis. The TG and GC were intravenously injected caudally with UK (Kailikang, Techpool Bio-Pharma Co., Ltd., 8.75×10^{-3} PNAU/kg) and puerarin (Zhejiang Zhenyuan Pharmaceutical Co., Ltd. Lot: H20020392, 100 mg/kg) 30 min after cerebral ischemia. The same volume of saline was simultaneously applied to the BC group.

The middle cerebral artery ischemia model was established using a modified Zea-Longer suture method. Approximately 3 ml/kg of 10% chloral hydrate was intraperitoneally injected for anesthesia. Rats were fixed in supine position and an incision was made in the neck midline to expose the left common carotid (CCA), internal carotid (ICA), and external carotid (ECA) arteries. The CCA was ligated proximal to the bifurcation. A small hole was cut 5 mm from the CCA bifurcation and a suture was inserted into the ICA. The insertion was stopped when resistance was felt at ~19 mm. At this point, the suture head was at the distal middle cerebral artery (MCA), forming the occlusion. After surgery, the corresponding drugs and saline were immediately intraperitoneally injected. After 2 h, ether was used as rapid anesthesia. The suture was gently pulled out ~10 mm to initiate reperfusion. The following were considered signs of successful establishment of the model: 1) contralateral limb paralysis and contralateral turning symptoms; 2) positive tail-hanging test; and 3) ipsilateral eye fisure decrease. Rats that did not satisfy these criteria were excluded from experimentation.

TTC staining

Seventy-two hours after ischemia/reperfusion, rats were anesthetized and decapitated to collect their brains. Brains were immediately frozen for 20 min. Starting from the anterior frontal pole, five 2-mm coronal slices were made from front to back with a tissue slicer. Slices were placed in TTC staining solution (chlorinolated-2.3.5 TTC, Sigma Co.) and incubated at 37°C for 30 min. Tissue sections were then placed in freshly prepared 10% formalin solution for fixation for 24 h. Normal brain tissue turned red, whereas infarcted brain tissue turned white. The slices were removed and arranged in sequence. Sample images were taken using a digital camera and uploaded into a computer.

Preparation of tissue sections

The rats were anesthetized using 10% chloral hydrate and placed on a dissecting table for each time point. Thoracotomy was performed on the left chest, and the left ventricle was...
catheterized. Blood was first removed using 4°C saline. Post-fixation was performed overnight using phosphate-buffered 4% paraformaldehyde at 4°C, followed by 20% and 30% phosphate-buffered sucrose incubation at 4°C until tissues sank. Consecutive frozen coronal 10-mm slices were made from the temporal lobe. One out of every four slices was used to perform TGF-β₁ immunohistochemical staining as a negative control.

Immunohistochemical staining and cell counting

Slices were washed twice with 0.01 mol/L phosphate-buffered saline and immersed into 3% H₂O₂ for 15 min, followed by droplet addition of non-immune animal serum blocking solution, primary anti-immune TGF-β₁ antibody, and secondary biotinylated goat anti-rabbit IgG, in that order. Reagent SABC was done using a TGF-β₁ protein immunohistochemical SABC kit (Wuhan Boster Biological Engineering Co., Ltd.). Finally, slices were counter-stained with hematoxylin and mounted with neutral gum. TGF-β₁-positive cell morphologies near the infarcted cortex were observed using an optical microscope (400×). The number of positive cells in each expression area field was counted under high-power magnification. Five slices from each rat were selected. Each slice was viewed at 5 randomly selected sites to count the positive cells near the infarcted cortex. At the same time, semi-quantitative image analysis was performed to calculate the final average number of positive cells. Peripheral serum hs-CRP was determined by immunoturbidimetry using hs-CRP buffer, calibrator solution, and hs-CRP antigen (Finland Orion Diagnostica). Serum was obtained during cardiac catheterization.

Statistical analysis

SPSS 13.0 software was used for statistical analysis. The data are expressed as x̄±s. Levene’s test was performed to determine the homogeneity of variance, with a test criteria of a=0.05. If the variance was homogenous, then the LSD test was performed; otherwise, Tamhane’s T2 test was performed. P<0.05 was considered a significant difference.

Results

Volume change calculation of ischemic lesion by TTC staining

Seventy-two hours after ischemia/reperfusion, infarcted lesions could be observed in the BC, TG, and GC groups. The infarcted zone was mainly located outside the parietal cortex and striatum, and no obvious bleeding was found in infarcted regions (Figure 1). The percentages of infarcted volumes are listed in Table 1.
Table 1. Cerebral infarcted volumes and percentages of each group 72 h after ischemia/reperfusion (mean ±SD).

| Group            | n  | Infarcted volumes (mm³) | Percentage (%) |
|------------------|----|-------------------------|----------------|
| Blank control    | 6  | 187.70±11.04            | 32.45±1.55     |
| Treatment        | 6  | 137.20±8.60             | 23.15±2.44**   |
| Puerarin control | 6  | 148.30±9.30             | 28.20±1.50*    |

** P<0.01 compared with blank control group; * P<0.05 between compared with puerarin control group.

Figure 2. Immunohistochemical staining 24 h after reperfusion (IHC ×400). The number of TGF-β1, positive cells increased in the left cortex, with deepened cytoplasmic staining. The deeply stained nuclei were obvious in the TG group. (A) BC; (B) GC; (C) TG.

Figure 3. Immunohistochemical staining 48 h after reperfusion (IHC ×400). (A) BC; (B) GC; (C) TG.
Table 2. Changes of TGF-\(\beta\)\(_1\) positive cells number at different time points after cerebral ischemia/reperfusion (mean ±SD).

| Group            | 6 h         | 12 h        | 24 h        | 48 h        | 72 h        |
|------------------|-------------|-------------|-------------|-------------|-------------|
| Blank control    | 25.35±1.55  | 31.35±1.30  | 51.30±1.51  | 57.45±1.75  | 54.35±1.15  |
| Treatment        | 29.55±1.35* | 36.45±1.74**| 56.25±1.85**| 64.35±2.14**| 58.25±2.35**|
| Puerarin control | 27.23±2.25  | 33.10±1.35  | 54.12±1.76  | 61.40±2.05  | 55.35±2.20  |

* P<0.05 and ** P<0.01 compared with blank control group and puerarin control group, respectively.

Table 3. Changes of serum hs-CRP level (mg/L) at different time points after cerebral ischemia/reperfusion (mean ±SD).

| Group       | 6 h      | 12 h     | 24 h     | 48 h     | 72 h     |
|-------------|----------|----------|----------|----------|----------|
| Blank control | 4.15±1.45 | 4.65±1.28 | 5.00±1.50 | 6.35±1.75 | 7.45±1.05 |
| Treatment   | 2.85±1.25* | 3.45±1.75* | 3.67±1.87* | 4.45±2.04** | 5.35±1.35** |
| Puerarin control | 3.55±1.32 | 4.05±1.68 | 4.25±2.61 | 5.05±0.54 | 6.35±1.23 |

* P<0.05 and ** P<0.01 compared with blank control group and puerarin control group, respectively.

**TGF-\(\beta\)\(_1\)-positive cells by light microscopy observation**

Six hours after cerebral ischemia/reperfusion, cerebral cortex TGF-\(\beta\)\(_1\) expression began to increase. Twenty-four hours after reperfusion, TGF-\(\beta\)\(_1\) expression significantly increased. Expression peaked at 48 h and declined at 72 h. The number of positive cells in GC significantly increased over time compared with BC (Figures 2, 3). The number of positive cells in the TG group at each time point significantly increased compared to the BC and GC groups (Table 2).

**Serum hs-CRP observation**

Six hours after cerebral ischemia/reperfusion, serum hs-CRP started to rise and continued increasing up to 72 h. The serum hs-CRP level in the GC group decreased over time compared to the BC group, and TG serum hs-CRP levels decreased over time compared with the BC and GC groups. The decreases at 48 and 72 h were statistically significant (Table 3, Figure 2).

**Discussion**

TGF-\(\beta\)\(_1\) is a cytokine with complex cellular functions, including growth regulation, proliferation, differentiation, inflammation response, and tissue repair. Scholars have speculated that TGF-\(\beta\)\(_1\) expression is correlated with blood vessel formation [3]. Several normal tissues or cells synthesize and release TGF-\(\beta\)\(_1\) in vivo. Astrocytes, microglia, and oligodendrocytes can produce TGF-\(\beta\)\(_1\). TGF-\(\beta\)\(_1\) expression is low in normal brain tissue. Increased TGF-\(\beta\)\(_1\) expression can be observed in ischemia/reperfusion under different conditions. Previous studies have shown that TGF-\(\beta\)\(_1\) mRNA increased at the injured sites 1 day after cerebral ischemia, reached a peak at 2 days, and disappeared by 7 days. Thus, increased neuronal TGF-\(\beta\)\(_1\) expression could be considered a neuronal survival sign [4]. The results of this experiment show that after ischemia/reperfusion, TGF-\(\beta\)\(_1\) increased rapidly and reached a peak 48 h after reperfusion. Therefore, it is clear that TGF-\(\beta\)\(_1\) is involved in the response to ischemia/reperfusion, which is consistent with the literature.

Numerous studies have shown that exogenous TGF-\(\beta\) administration effectively reduces infarct volume after cerebral hypoxic/ischemic injuries in mice [5,6]. We are aware of 5 possible protective mechanisms of TGF-\(\beta\)\(_1\) against cerebral ischemic injury. The first protective mechanism is intracellular Ca\(^{2+}\) concentration reduction, which protects nerve cells from glutamate cytotoxicity and increases neurons in the ischemic penumbra for long-term survival [7]. The second protective mechanism is that TGF-\(\beta\)\(_1\) is an important regulating factor in brain injury repair that (a) produces a variety of biological effects in vivo and in vitro on glial cells and neurons, (b) regulates extracellular matrix synthesis and secretion by microglia, astrocytes [8], and (c) promotes tissue repair. In addition, TGF-\(\beta\)\(_1\) regulates reactive oxygen species production through microglia [9]. The third protective mechanism is that TGF-\(\beta\)\(_1\) is a powerful vascular proliferation regulator that induces angiogenesis through basic fibroblast growth factor and macrophages, thereby facilitating necrotic tissue transportation and nerve remodeling [10–12]. The fourth protective mechanism is that TGF-\(\beta\)\(_1\) can antagonize neuronal apoptosis mediated by staurosporine and increased Bcl-2 protein expression. Zhu recently proposed that the primary TGF-\(\beta\)\(_1\) anti-apoptotic mechanism was through activation of nuclear transcription factor NF-kB. Thus, TGF-\(\beta\)\(_1\) inhibits activation of caspase-3 [13], or inhibits BAD expression, thereby increasing BAX phosphorylation to inhibit...
The fifth protective mechanism is that TGF-β increases the chemotaxis of tumor necrosis factor-α and its receptors to inflammatory cells, thereby exhibiting significant regulatory functions in cell migration, inflammation, and immune responses [15–17]. In addition, as an anti-inflammatory factor, TGF-β rapidly induces the anti-hypoxia response shortly after cerebral hypoxia, which effectively prevents the progress of adverse reactions induced by hypoxia. Thus, TGF-β is even stronger than IL-10 [18]. However, TGF-β can also damage central nervous system function. For example, TGF-β is related to disruption of the blood-nerve and blood-brain barrier in diabetic neuropathy [19]. The effects of TGF-β on glial cells and leptomeningeal mesothelial cells are less studied.

CRP is a sensitive acute-phase protein synthesized by the liver. CRP is a sensitive predictor of inflammation and a marker of atherosclerosis. Increased hs-CRP levels can prompt a significant increase in the content and activity of serum pro-inflammatory cytokines. Immunoassay lowers the detection limit of hs-CRP to the 0.005–0.10 mg/L range. CRP measured using this method is called hs-CRP, which is a valuable cerebral ischemia predictor. This marker fully and sensitively reflects the presence of inflammation. Clinical studies have found increased serum hs-CRP levels in acute cerebral infarction TOAST subtypes [20]. Korean scholars divided 886 cases of stroke caused by middle cerebral artery thrombosis into cortical, lacunar, and deep perforating branch and watershed infarctions. Serum hs-CRP detection revealed that serum hs-CRP levels were increased in cortical infarction compared with the other 3 types [21]. This phenomenon is probably caused by the intense inflammatory response resulting from large-artery atherosclerosis. Another scholar compared the correlation between hs-CRP levels and infarcted volume and found a positive relationship between the 2. The majority of clinical scholars use hs-CRP as an indicator for assessing stroke prognosis, and recurrence [22–24]. A number of scholars have studied guinea pig brain specimens and blood-brain barrier in vitro cell culture models, which show that CRP induces blood-brain barrier damage, resulting in cerebral edema through a signal transduction pathway [25]. In the present study, the trend of serum hs-CRP levels shortly after cerebral ischemia was measured. However, further study is required to elucidate the relationship between disease severity and long duration after infarction.

UK is a Class I drug that was developed to treat cerebral infarction. UK, a glycoprotein extracted and purified from human urine, can selectively expand arterioles in ischemic areas, promote vascular regeneration, establish collateral circulation, and improve ischemic area perfusion. Furthermore, UK enhances red blood cell deformability and oxygen dissociation ability, promotes tissue glucose utilization, and inhibits hyperactive platelet aggregation and hematopexis hyperthyroidism. UK also suppresses neuron and glial apoptosis and promotes endogenous nerve regeneration, thereby accelerating the recovery of neurological functions [26–28]. In animal models of cerebral ischemia, UK was confirmed to promote the angiogenesis and opening of collateral circulation, reduce inflammatory cell infiltration, reduce infarct size and cerebral edema, promote the migration of glial cells into the ischemic area, and protect neurons endangered by ischemia [29,30]. In the current study, the cerebral ischemia/reperfusion injury model was established to study the effects of UK intervention. The results showed that the infarct volume in the TG group was significantly reduced compared to the BC and GC groups. The TGF-β expression around infarcted brain tissues was significantly upregulated compared with the BC and GC groups. Serum hs-CRP levels in TG at all time points decreased compared with those in the GC and BC groups. A significant decrease was observed at the 48 h and 72 h time points.

Conclusions

These findings indicate that early UK intervention promotes TGF-β activation, increases TGF-β expression, and inhibits excessive inflammatory response, thereby promoting brain tissue repair and reducing infarct volume. This study showed UK regulates inflammatory factor changes, which may be a neuroprotective mechanism of UK.

Conflict of interest

All authors have no conflict of interest regarding this paper.

References:

1. Rodrigues ES, Silva RF, Martin RP et al: Evidence that kinin B2 receptor expression is upregulated by endothelial overexpression of B1 receptors. Peptides, 2013; 42: 1–7
2. Pál G, Vincze C, Renner É et al: Time course, distribution and cell types of induction of transforming growth factor betas following middle cerebral artery occlusion in the rat brain. PLoS One, 2012; 7: e46731
3. Weinberg DG, Arnaout OM, Rahme RI et al: Moyamoya disease: a review of histopathology, biochemistry, and genetics. Neurosurg Focus, 2011; 30: E20
4. Naylor M, Bowen KK, Sailor KA et al: Preconditioning-induced ischemic tolerance stimulates growth factor expression and neurogenesis in adult rat hippocampus. Neurochem Int, 2005; 47: 565–72
5. Gleim M, Mausberg AK, Lee Ji et al: Macrophages prevent hemorrhagic infarct transformation in murine stroke models. Ann Neurol, 2012; 71: 743–52
6. Ma M, Ma Y, Yi X et al: Intranasal delivery of transforming growth factor-beta1 in mice after strokereduces infarct volume and increases neuronal differentiation in the subventricular zone. BMC Neurosci, 2008; 9: 117
7. Turovskaya MV, Turovsky EA, Zinchenko VP et al: Repeated brief episodes of hypoxia modulate the calcium responses of ionotropic glutamate receptors in hippocampal neurons. Neurosci Lett, 2011; 496: 11–14
8. Pang L, Ye W, Che XM et al: Reduction of inflammatory response in the mouse brain with adenosinergic-mediated transforming growth factor-β1 expression. Stroke, 2001; 32: 544–52
9. Qian L, Wei SJ, Zhang D et al: Potent anti-inflammatory and neuroprotective effects of TGF-beta1 are mediated through the inhibition of ERK and p47phox-Ser345 phosphorylation and translocation in microglia. J Immunol, 2008; 181: 660–68
10. Oyamada N, Sone M, Miyashita K et al: The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia. Endocrinology, 2008; 149: 3764–77
11. Netto GC, Bleib CB, Hilbig A, Coutinho LM: Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD105/endoglin) and CD34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas. Neuropathology, 2008; 28: 17–23
12. Dhandapani KM, Brann DW: Transforming growth factor-β1 neuroprotective factor in cerebral ischemia. Cell Biochem Biophys, 2003; 39: 13–22
13. Zhu Y, Culmsee C, Klumpp S, Krieglstein J: Neuroprotection by transforming growth factor-beta 1 involves activation of nuclear factor-kappa B through phosphatidylinositol-3-OH kinase/Akt and mitogen-activated protein kinase-extracellular signal regulated kinase1,2 signaling pathways. Neuroscience, 2004; 123: 897–906
14. An S, Hishiwaka Y, Koji T: Induction of cell death in rat small intestine by ischemia reperfusion: differential roles of Fas/Fas ligand and Bcl-2/Bax systems depending upon cell types. Histochem Cell Biol, 2005; 123: 249–61
15. Welser JV, Li L, Milner R: Microglial activation state exerts a biphasic influence on brain endothelial cell proliferation by regulating the balance of TNF and TGF-β1. J Neuroinflammation, 2010; 7: 89
16. Sieber MW, Claus RA, Witte OW, Frahn C: Attenuated inflammatory response in aged mice brains following stroke. Curr Neurovasc Res, 2008; 5: 214–23
17. Levin SG, Gudukhin OV: Anti-inflammatory cytokines, TGF-β1 and IL-10, exert anti-hypoxic action and abolish posthypoxic hyperexcitability in hippocampal slice neurons: Comparative aspects. Exp Neurol, 2011; 232: 329–32
18. Shimizu F, Sano Y, Tominaga O et al: Advanced glycation end-products disrupt the blood-brain barrier by stimulating the release of transforming growth factor-β by pericytes and vascular endothelial growth factor and matrix metalloproteinase-2 by endothelial cells in vitro. Neurobiol Aging, 2013; 34: 1902–12
19. Tuttolomondo A, Di Raimondo D, Pecoraro R et al: Inflammation in ischemic stroke subtypes. Curr Pharm Des, 2012; 18: 4289–310
20. Yoon SR, Bang OY, Hong JM et al: Non-conventional risk factors were associated with infarct patterns in ischemic stroke. Clin Neurol Neurosurg, 2009; 111: 134–39
21. Dewan KR, Rana PV: C-reactive protein and early mortality in acute ischemic stroke. Kathmandu Univ Med J, 2011; 9: 252–55
22. Andersson J, Johansson L, Ladenvall P et al: C-reactive protein is a determinant of first-ever stroke, prospective nested case-reference study. Cerebrovasc Dis, 2009; 27: 544–51
23. Chen PC, Chien KL, Hsu HC et al: Metabolic syndrome and C-reactive protein in stroke prediction: A prospective study in Taiwan. Metabolism, 2009; 58: 772–78
24. Kuilmann CR, Librizzi L, Closhen D et al: Mechanisms of C-reactive protein-induced blood-brain barrier disruption. Stroke, 2009; 40: 1458–66
25. Chen PC, Chien KL, Hsu HC et al: Metabolic syndrome and C-reactive protein in stroke prediction: A prospective study in Taiwan. Metabolism, 2009; 58: 772–78
26. Leeb-Lundberg LM, Marceau F, Müller-Esterl W et al: International union of pharmacology. XLI. Classification of the kinin receptor family: From molecular mechanisms to pathophysiological consequences. Pharmacol Rev, 2005; 57: 27–77
27. Emanuelli C, Madeddu P: Angiogenesis therapy with human tissue kallikrein for the treatment of ischemic diseases. Arch Mal Coeur, 2004; 97: 679–87
28. Xia CF, Yin H, Borlongan CV et al: Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension, 2004; 43: 452–59
29. Gröger M, Lebesgue D, Pruneau D et al: Release of bradykinin and expression of kinin B2 receptors in the brain: role for cell death and brain edema formation after focal cerebral ischemia in mice. J Cereb Blood Flow Metab, 2005; 25: 978–89
30. Chen ZB, Huang DQ, Niu FN et al: Human urinary kallidinogenase suppresses cerebral inflammation in experimental stroke and downregulates nuclear factor-kappaB. J CerebBlood Flow Metab, 2010; 30: 1356–65

Indexed in: [Current Contents/Clinical Medicine] [SCIE Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS] [Index Copernicus]